Lynx Capital Group’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.63M Sell
18,234
-289
-2% -$67.4K 1.87% 15
2026
Q1
$4.53M Sell
18,523
-221
-1% -$51.5K 2.11% 14
2025
Q4
$3.88M Sell
18,744
-27
-0.1% -$5.34K 1.78% 20
2025
Q3
$3.48M Buy
18,771
+75
+0.4% +$12.8K 1.61% 24
2025
Q2
$2.86M Sell
18,696
-14
-0.1% -$2.15K 1.38% 37
2025
Q1
$3.1M Buy
18,710
+2,978
+19% +$466K 1.6% 26
2024
Q4
$2.28M Sell
15,732
-45
-0.3% -$6.97K 1.31% 39
2024
Q3
$2.56M Buy
15,777
+356
+2% +$56.7K 1.66% 32
2024
Q2
$2.25M Buy
15,421
+28
+0.2% +$4.16K 1.56% 30
2024
Q1
$2.44M Buy
15,393
+824
+6% +$131K 1.64% 29
2023
Q4
$2.28M Buy
+14,569
New +$2.23M 1.66% 27

Other funds holding JNJ

Lynx Capital Group's JNJ Position: Q2 2026 in Review

Lynx Capital Group reduced its Johnson & Johnson (JNJ) stake by 1.6% in Q2 2026, selling an estimated $67.4K and leaving 18,234 shares worth $4.63M. The position accounts for 1.87% of the portfolio, ranked #15.

Lynx Capital Group first reported a position in JNJ in Q4 2023 and has held it in 11 quarters since. 4,503 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Lynx Capital Group held 18,234 shares of Johnson & Johnson worth $4.63M as of Q2 2026.
  • Lynx Capital Group sold 289 Johnson & Johnson shares in Q2 2026, an estimated $67.4K.
  • Johnson & Johnson made up 1.87% of Lynx Capital Group's portfolio in Q2 2026, its #15 holding.
  • Lynx Capital Group first reported a position in Johnson & Johnson in Q4 2023 and has held it in 11 quarters since.
  • 4,503 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Lynx Capital Group's 13F filing for Q2 2026, filed 12 Aug 2026.